Supriya Lifesciences targets Brazil, eyes Rs 200 crore sales in 2-3 years

This ambition follows the company's recent approval from Anvisa (Brazilian health regulatory agency), which has facilitated its entry into the Brazilian market

Manufacturer of active pharmaceutical ingredients (APIs) Supriya Lifesciences aims to add up to Rs 200 crore in sales from new product launches in Brazil in two to three years, following approval from the country’s health regulatory agency Anvisa, which has facilitated its entry into the Brazilian market.
 

Anvisa, responsible for auditing and registering pharmaceuticals in Brazil, recently completed an inspection of the Mumbai-based company’s manufacturing unit in Lote Parshuram. The audit concluded with zero observations, a significant achievement for the company.

“Our recent approval from Anvisa positions Supriya as a preferred supplier in the Brazilian market, enabling faster registration turnaround times for new products,” said Saloni Satish Wagh, whole-time director of Supriya Lifesciences.

On expansion plans, Wagh said, “The company has eight APIs in the pipeline, with registration expected within nine to twelve months. Our focus is on markets where registration was previously lacking or semi-regulated. We are particularly targeting anesthetics, anti-diabetics, and anti-anxiety/anti-depression drugs (narcotics), aiming to capture 10 per cent of market share in specific product segments over the next two to three years.”

The company also has plans to open a second research and development centre in Amarnath which will primarily manufacture intermediates for their final APIs. The pharmaceutical company is expanding its facility in Ratnagiri (Lote Parshuram), where all 32 APIs are manufactured. This expansion includes adding a new block, which will increase the capacity by 300 kilometres, totaling 900 kilometres upon completion.

Supriya Lifesciences is engaged in the early research and development of two to three cancer drugs. These efforts are focused on molecules expected to go off-patent in 2027-28. In October last year, the company announced a collaboration with the Kalinga Institute of Industrial Technology (KIIT) in Bhubaneswar to develop Quickblue, a cancer detection kit for oral cancer in India. The kit is expected to be commercially available in the next three years. The company aims to capture 1 to 2 per cent share of the global cancer market.